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Purpose: The goal of this study was to identify mutations in X-chromosomal genes associated with retinitis pigmentosa
(RP) in patients from Germany, The Netherlands, Denmark, and Switzerland.
Methods: In addition to all coding exons of RP2, exons 1 through 15, 9a, ORF15, 15a and 15b of RPGR were screened
for mutations. PCR products were amplified from genomic DNA extracted from blood samples and analyzed by direct
sequencing. In one family with apparently dominant inheritance of RP, linkage analysis identified an interval on the X
chromosome containing RPGR, and mutation screening revealed a pathogenic variant in this gene. Patients of this family
were examined clinically and by X-inactivation studies.
Results: This study included 141 RP families with possible X-chromosomal inheritance. In total, we identified 46 families
with pathogenic sequence alterations in RPGR and RP2, of which 17 mutations have not been described previously. Two
of the novel mutations represent the most 3’-terminal pathogenic sequence variants in RPGR and RP2 reported to date.
In exon ORF15 of RPGR, we found eight novel and 14 known mutations. All lead to a disruption of open reading frame.
Of the families with suggested X-chromosomal inheritance, 35% showed mutations in ORF15. In addition, we found five
novel mutations in other exons of RPGR and four in RP2. Deletions in ORF15 of RPGR were identified in three families
in which female carriers showed variable manifestation of the phenotype. Furthermore, an ORF15 mutation was found in
an RP patient who additionally carries a 6.4 kbp deletion downstream of the coding region of exon ORF15. We did not
identify mutations in 39 sporadic male cases from Switzerland.
Conclusions: RPGR mutations were confirmed to be the most frequent cause of RP in families with an X-chromosomal
inheritance pattern. We propose a screening strategy to provide molecular diagnostics in these families.
Retinitis pigmentosa (RP) is clinically characterized by
night  blindness,  concentric  constriction  of  visual  fields,
pigment deposits predominantly in the midperiphery of the
retina, and attenuation of retinal vessels. It affects one in
3000–4000 individuals and can be caused by mutations in
more than 40 genes (Retnet; Retina International). The disease
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may be inherited as autosomal recessive, autosomal dominant,
or X-linked (XL) traits. Approximately 50% of the cases are
sporadic [1].
Most  mutations  lead  to  a  similar  phenotype,  making
genotype-phenotype  correlations  difficult.  Nevertheless,
mutations  in  XLRP  genes  are  associated  with  a  severe
phenotype in terms of onset and progression of the disease.
The  two  known  RP-associated  X-chromosomal  genes  are
designated  RPGR  (OMIM  312610)  and  RP2  (OMIM
312600) [2-4]. Additional loci on the X-chromosome have
been  mapped,  but  the  respective  genes  have  not  been
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1081identified [5-7]. Indeed, most XLRP cases can be explained
by mutations in RPGR and RP2 accounting for up to 80% and
20%  of  disease  alleles,  respectively.  Moreover,  RPGR
mutations underlie 10–20% of all familial RP cases, which is
higher than most other single RP loci [8,9].
The RPGR gene is composed of 23 exons, including the
alternatively spliced exons 9a, ORF15, 15a, and 15b [10-12].
Exon ORF15 is predominantly found in transcripts of the
retina and brain [13], whereas mRNAs including exons 1–19
are widely expressed [12]. The N-terminal part of RPGR
contains  a  domain  homologous  to  the  regulator  of
chromosome  condensation  1  (RCC1),  the  guanine-
nucleotide-exchange factor for the GTPase Ran that has been
shown  to  be  important  for  the  association  with  binding
partners. RPGR mutations are most frequently found in exon
ORF15, followed by exons 1–15 [9-12,14,15]. No mutations
have been identified in exons 16–19 so far. ORF15 contains
Figure 1. Location of novel RPGR and RP2 mutations identified in
this study. The schematic drawing shows novel mutations and their
approximate  positions  in  RPGR  (A)  and  RP2  (B).  Alternatively
spliced exons are shown in light gray, whereas other exons are
depicted in black.
a purine-rich domain of approximately 1050 base pairs, which
is  predicted  to  encode  a  repetitive  glycine  and  glutamate
region at the C-terminus of the protein. In human, out of frame
deletions, duplications, or insertions are frequently found in
ORF15, whereas nonsense mutations are rare and disease-
relevant missense mutations have not been described. Two
canine animal models of ORF15 frame-shift mutations have
been published and closely resemble the human phenotype in
terms of disease onset and progression [16,17].
RT–PCR studies have suggested that splicing of both,
constitutive exons and the ORF15-internal repeat of RPGR,
generates numerous transcript variants [11,18]. This indicates
that splicing is an important regulator of RPGR function.
Recently, we have shown that a novel isoform of RPGR,
including exon 9a, is expressed predominantly in cones of the
human  retina  [10],  which  may  explain  why  mutations  in
RPGR can also lead to a predominant degeneration of cones
starting in the central part of the retina [19-22]. These findings
extend  the  phenotypic  spectrum  associated  with  RPGR
mutations and suggest a specific role of RPGR isoforms in the
survival of cones and rods of the human retina.
RP2  is  composed  of  five  coding  exons,  which  are
translated to a widely expressed protein of 350 amino acids
[4]. The function of RP2 is not completely understood, but it
shows homology to cofactor C, a protein involved in the
ultimate step of gamma-tubulin folding, and interacts with
ADP ribosylation factor-like 3 [23]. Posttranslational acyl
modifications at the N-terminus of RP2 mediate its targeting
to the plasma membrane, and the disruption of the acylation
site leads to RP [24]. The majority of pathogenic sequence
alterations  found  in  RP2  represent  truncating  mutations,
whereas missense mutations often locate to the cofactor C-like
domain of RP2.
The  present  study  describes  the  results  of  mutational
screenings  in  RP  families  with  possible  XL  inheritance
patterns. In addition to known sequence alterations, we found
several novel mutations in RPGR and RP2 and characterized
an XLRP family with variable disease expression in female
carriers. We identified a microdeletion breakpoint in addition
to an ORF15 frameshift mutation in a single RP patient. A
screening strategy for molecular diagnostic testing in patients
or  families  with  presumed  X-chromosomal  inheritance  is
discussed.
METHODS
Patients: Informed consent was obtained from each patient
and  healthy  control  after  explanation  of  the  nature  and
possible  consequences  of  the  study.  Blood  samples  were
collected to perform routine molecular genetic testing for
genes  associated  with  RP  or  related  retinal  diseases.  We
collected a panel of 141 retinal degeneration patients with
possible  XL  inheritance  patterns.  Among  those  were  39
patients  without  history  of  additional  affected  family
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males preferentially affected, and 90 cases with possible XL-
inheritance showing at least two affected male family member
and  no  male-to-male  transmission.  The  latter  group  also
included  male  sibships.  Six  simplex  cases  were  clinically
diagnosed with cone-rod dystrophy, whereas all others were
diagnosed with RP. Clinical evaluations of patients included
slit  lamp  examination,  funduscopy,  and  Ganzfeld-
electroretinography  (ERG).  Ganzfeld-ERG  was  performed
according to standards of the International Society for Clinical
Electrophysiology of Vision using a LKC-UTAS 3000 ERG
device  (LKC  Technologies  Inc.,  Gaithersburg,  MD)  or  a
Nicolet Spirit examination unit (Nicolet, Madison, WI) [25,
26]. For scotopic ERG recordings, we employed a phase of
dark-adaptation  preceded  by  single  dim  white  and  bright
white flashes for stimulation. Bright white flashes were used
for single responses and 30 Hz flicker responses in photopic
ERG  measurements.  Goldmann  perimetry  (Goldmann
perimetry module on the Octopus 101 visual field testing
device;  Haag-Streit,  Köniz,  Switzerland),  fundus
photography, and best corrected visual acuity testing were
often performed to complement the clinical characterization.
Furthermore,  we  collected  blood  samples  from  15
individuals of an XLRP family, segregating the disease in
three  generations  (index  25085).  In  this  family,  ocular
examinations, as approved by the ethics committee of the
Institute of Human Genetics of the University Hospital of
Cologne, were done in II:3, III:7, and III:12 and included
refraction, best corrected visual acuity, intraocular pressure,
slit-lamp  biomicroscopy,  funduscopy,  and  color
discrimination test. ERG, dark adaptation and visual field
were also analyzed in these three patients.
Linkage  analysis  for  an  XLRP  locus  with  variable
heterozygote manifestation: We analyzed DNA samples from
15  individuals  of  a  family  that  segregates  RP  in  three
generations  (index  patient  25085).  PCR  fragments  of
polymorphic  microsatellite  markers  were  amplified  using
fluorescent-labeled  oligonucleotides  and  analyzed  on  an
ABI-377 DNA sequencer (Applied Biosystems, Darmstadt,
Germany).  Genotypes  were  determined  by  GeneScan
software (Applied Biosystems). Data provided by the GDB
Human Genome Database were used as reference for allele
sizes.  Segregation  analysis  was  performed  by  genotyping
locus-specific microsatellite markers for the following AD RP
genes:  NRL  (RP27),  CRX,  RP1,  PIM1K  (RP9),  IMPDH1
(RP10),  CA4  (RP17),  and  FSCN2.  Markers  were  not
informative for PRPF31, RDS, and RHO. Therefore, the entire
coding regions of the corresponding genes were sequenced in
the index patient (III:7). In PRPF3 and PRPF8, mutations
have only been described in exons 11 and 42, respectively.
These exons were directly sequenced. Primer sequences and
PCR conditions are available upon request. The RP31 locus
had not yet been described when this study was performed and
thus, was not analyzed [27].
To map the disease locus, we performed a genome-wide
linkage  analysis  using  the  Affymetrix  GeneChip  Human
Mapping 10K Array, version 2.0 (Affymetrix, Santa Clara,
CA). Genotypes were called by the GeneChip DNA Analysis
Software (GDAS v2.0; Affymetrix). Genders of samples were
verified  by  counting  heterozygous  single  nucleotide
polymorphisms (SNPs) on the X chromosome. Relationship
errors were evaluated with the help of the program Graphical
Relationship  Representation  [28].  The  program  PedCheck
was applied to detect Mendelian errors [29], and data for SNPs
with  such  errors  were  removed  from  the  data  set.  Non-
Mendelian errors were identified by using the program Merlin
[30] and unlikely genotypes for related samples were deleted.
Nonparametric  linkage  analysis  using  all  genotypes  of  a
chromosome  simultaneously  was  performed  with  Merlin.
Parametric linkage analysis was performed by a modified
version  of  the  program  Genehunter  2.1  [31,32]  through
stepwise use of a sliding window with sets of 100 SNPs and
by the program Allegro [33] assuming autosomal dominant
inheritance  with  reduced  penetrance  and  a  disease  allele
frequency  of  0.0001.  Haplotypes  were  reconstructed  with
Allegro  or  Merlin  and  presented  graphically  with
HaploPainter [34]. All data handling was performed using the
graphical interface Alohomora [35].
Mutation screening: The genomic DNA of the index patient
panel  was  screened  for  disease-associated  sequence
alterations in exon ORF15 of RPGR by direct sequencing of
PCR products. A single PCR fragment, spanning the entire
coding region of exon ORF15, was amplified from 100 ng
genomic  DNA  using  primers  ORF15-F3  and  ORF15-R6
(Appendix  1).  As  described  elsewhere,  patients’  genomic
DNA was either extracted by a salting out method or by
affinity  purification  mediated  by  magnetic  beads  [36,37].
PCR was performed with either HotfireTaq (Solis Biodyne,
Tartu,  Estonia)  or  HotstarTaq  Polymerase  (Qiagen  AG,
Hombrechtikon,  Switzerland)  as  recommended  by  the
manufacturers. Q-solution and 3µM MgCl2 were added to the
reaction  mixture.  Cycling  conditions  of  the  PCR  were
conducted for 45 cycles as follows: initial denaturation 95 °C
for 15 min, denaturation 95 °C for 45 s, annealing 60 °C for
1 min, elongation 72 °C for 3.5 min. Subsequently, the PCR
fragments were sequenced (ABI 3100; Applied Biosystems,
Rotkreuz, Switzerland) with primers ORF15-R7b, -R8b, -R9,
-R5, -R4, and -F10 (Appendix 1). The sequenced PCR profiles
were  compared  to  the  RPGR  reference  database  entry
NM_001034853  (NCBI  database).  If  genomic  DNA  were
available only from female members of the family, sequence
analysis  of  ORF15  was  occasionally  not  complete,  since
polymorphic  heterozygote  deletions  or  duplications  may
resulted in overlapping sequence spectrums. If no mutations in
RPGR exon ORF15 were detected, we subsequently analyzed
all coding exons of RP2 and the RPGR exons 1 through 15,
9a, 15a, and 15b, including flanking intronic sequences. RP2
mutational screening was performed using either single strand
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[4]  (Appendix  1).  Long-range  PCR  was  conducted  as
recommended by the manufacturers (Expand long range PCR
system;  Roche,  Mannheim,  Germany)  using  the  primer
ORF15-F10 and ORF15–15a-R10 (annealing temperature of
60 °C; elongation time of 10 min). Potential mutations of RP2
or RPGR were verified by sequence analysis of the respective
position in either 100 or 300 control alleles. The database entry
BC043348 was used as reference sequence for RP2 mutation
analysis. The identified nucleotide substitutions and protein
consequences are described as recommended (for guidelines
see  the  Human  Genome  Variation  Society)  and,  to  be
comparable to previously published data, as suggested by
Sharon et al. [15] or Bader et al. [9].
X-chromosome  inactivation  studies:  A  nonrandom  X-
inactivation may explain variable phenotypic expression in
females  that  carry  a  single  RPGR  mutation.  To  test  this
possibility, we performed X-chromosome inactivation studies
and  examined  the  methylation  patterns  at  the  androgen
receptor (AR) locus as described before [38]. Briefly, for each
proband,  we  prepared  two  reactions.  In  the  first,  400  ng
genomic DNA were digested with HpaII (8 U) in a total
volume of 10 μl for 30 min at 37 °C. In the second reaction,
150  ng  genomic  DNA  were  incubated  without  enzyme.
Subsequent  PCR  amplification  was  done  using
oligonucleotide primers AR-A (5′-CTT TCC AGA ATC TGT
TCC AG-3′) and AR-B (5′-AAG GTT GCC TGT TCC TCA
TC-3′)  in  a  PTC-thermal  cycler  (MJ  Research,  BioRad,
München, Germany) at 95 °C for 1 min, 55 °C for 1 min, and
72 °C for 1 min for 35 cycles. About 2–10 μl of the product
was mixed with 2–6 μl loading buffer and run at 70 W for 3–
3.5  h  on  an  8%  nondenaturing  polyacrylamide  gel.  After
electrophoresis, the gel was silverstained for evaluation. DNA
samples of a male control as well as two female controls with
previously confirmed unilateral X-inactivation were included
into the analysis.
RESULTS
Identification of mutations: We analyzed DNAs from 141
patients  with  retinal  degeneration  for  mutations  in  X-
chromosomal RP-associated genes. DNA was collected from
various  geographical  regions,  including  Germany,
Switzerland, Denmark, and The Netherlands and contained 90
samples  from  families  indicative  for  an  XL-inheritance
pattern.  Within  the  subgroup  of  90  index  patients,  we
identified  31  (35%)  mutations  in  exon  ORF15  of  RPGR.
Among these ORF15 mutations, 14 sequence alterations had
been reported previously, whereas eight were novel mutations
(Figure 1A, Table 1). In addition to two nonsense mutations
leading  to  a  premature  stop  codon,  we  identified  three
different duplications, 16 distinct deletions, and one insertion.
All cause a frameshift and were predicted to result in altered
amino acids followed by a premature stop codon (Table 1).
We excluded that additional nucleotide variations in RP2 and
RPGR may explain the phenotype of RP in patients with
ORF15  mutations  and  performed  mutation  screenings  in
exons 1 through 15, 9a, 15a, and 15b of RPGR and all coding
exons  of  RP2.  In  addition  to  pathogenic  mutations,  we
identified several polymorphic sequence alterations (Table 2
and Table 3).
The deletion c.2548delG in exon ORF15 of RPGR was
detected in two independent families. In one of them (index
patient 24731), the mother as well as three of her sons were
affected  by  RP,  whereas  one  son  and  one  daughter  were
unaffected. Since the mother was affected, this suggests that
female carriers of this mutation can be affected by RP. The
second family, in which we found the mutation c.2548delG in
the  index  patient  10005,  showed  variable  disease
manifestation  in  female  carriers.  The  finding  that  two
apparently unrelated families with the same RPGR mutation
showed  disease  expression  in  female  carriers,  suggests  a
genotype-phenotype correlation. Further families with this
mutation need to be analyzed to verify this observation.
In patient 2557, we identified the single bp deletion c.
3395delA at the 3’ end of exon ORF15 (Table 1). Remarkably,
the same patient had been shown to have an approximately
6.4  kb  deletion  in  the  RPGR  gene  [39].  We  now  have
determined the breakpoints in the genomic DNA to verify
whether the 6.4 kb deletion, in addition to c.3395delA, affects
the exon ORF15 coding region. We performed long-range
PCR and sequencing and found that the 6.4 kb deletion started
27 bp after the stop codon of exon ORF15 and ended 72 bp
downstream of exon 15a (Figure 2A,B,C). Thus, the larger
deletion of patient 2557 includes 6419 bp and removes exon
15a and 15b of RPGR, but does not affect the coding region
of exon ORF15. In contrast, the mutation c.3395delA removes
an  adenine  62  bp  upstream  of  the  ORF15  stop  codon.
Consequently,  the  mutation  was  predicted  to  result  in  a
frameshift at the 3’-terminal end of ORF15, which affects only
the last 21 amino acids and results in a premature stop codon
after inclusion of 19 RPGR-unrelated amino acids. The two
deletions found in the male index patient 2557 locate to one
allele at a distance of only 90 bp within RPGR.
In  XLRP  patients  without  an  ORF15  mutation,  we
screened the five exons of RP2 by direct sequencing and
identified five pathogenic sequence variations, which either
lead to a frameshift, an altered amino acid composition, or a
presumed splice defect of RP2 (Figure 1B, Table 1).
DNA from index patients who did not show mutations in
ORF15 and RP2 were analyzed for sequence variations in
exons 1 through 15, 9a, 15a, and 15b of RPGR. We were able
to identify pathogenic sequence alterations in six additional
XLRP cases. One mutation, found in exon 8, deletes two bp
of codon 271, introducing a frameshift to the transcript. Three
mutations affect intronic sequences close to RPGR exons and
presumably  result  in  splice  defects.  Furthermore,  two
mutations alter a glycine in either exon 6 or 7 of RPGR (Figure
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1084TABLE 1. MUTATIONS
 FOUND
 IN RPGR 
AND
 RP2 
IN X-LINKED RETINITIS PIGMENTOSA
 FAMILIES
Patient ID        (exon/intron)
Gene
ORF15 mutation (1)
ORF15 protein
change (1)
Mutation (2)
Protein
change (2)        reported by
Mutation first
XRP51
RP2 (exon 1)
-
-
c.13_15del3
p.Phe5del
novel mutation
XRP6
RP2 (intron 2)
-
-
c.769-3C>A
-
novel mutation
XRP21*****
RP2 (exon 2)
-
-
c.358C>T
p.Arg120X
Hardcastle et al., 1999 [
51]
XRP26
RP2 (intron 3)
-
-
c.884-1G>C
-
novel mutation
24748
RP2 (exon 4)
-
-
c.968delAinsTCC
p.Lys323fs
novel mutation
XRP11
RPGR (intron 2)
-
-
c.154+3del4
-
novel mutation
XRP19
RPGR (intron 4)
-
-
c.311-9del13
-
novel mutation
24750
RPGR (exon 6)
-
-
c.593G>A
p.Gly198Glu
novel mutation
XRP16
RPGR (exon 7)
-
-
c.644G>T
p.Gly215Val
Vervoort et al., 2002 [45]
24739
RPGR (intron 7)
-
-
c.779-5T>G
-
novel mutation
24746
RPGR (exon 8)
-
-
c.812_813delTT
p.Phe271fs
novel mutation
XRP32
RPGR (ORF15)
g.ORF15+180_181insC
ORF15Gly60fs
c.1933_1934insC
p.Gly645fs
novel mutation
XRP70
RPGR (ORF15)
g.ORF15+482_485delAGAA
ORF15Glu162fs
c.2235_2238delAGAA
p.Glu747fs
novel mutation
2460*****
RPGR (ORF15)
g.ORF15+483_484delGA
ORF15Glu161fs
c.2236_2237delGA
p.Glu746fs
Vervoort et al., 2000 [11]
24520
RPGR (ORF15)
g.ORF15+515delA
ORF15Glu172fs
c.2268delA
p.Glu757fs
novel mutation
2554
RPGR (ORF15)
g.ORF15+517_518delAG
ORF15Glu172fs
c.2270_2271delAG
p.Glu757fs
Sharon et al., 2003 [15]
XRP72
RPGR (ORF15)
g.ORF15+568_577delAGAGGAAAAA
ORF15Glu189fs
c.2321_2330delAGAGGAAAAA
p.Glu774fs
novel mutation
XRP48
RPGR (ORF15)
g.ORF15+587_588delAG
ORF15Arg195fs
c.2340_2341delAG
p.Arg780fs
Bader et al., 2003 [9]
25085° ****
RPGR (ORF15)
g.ORF15+652_653delAG
ORF15Glu217fs
c.2405_2406delAG
p.Glu802fs
Vervoort et al., 2000 [11]
XRP13
RPGR (ORF15)
g.ORF15+673_674delAG
ORF15Glu224fs
c.2426_2427delAG
p.Glu809fs
Vervoort et al., 2000 [11]
24751
RPGR (ORF15)
g.ORF15+690G>T(stop)
ORF15Glu230Ter
c.2443G>T
p.Glu815X
novel mutation
XRP27
RPGR (ORF15)
g.ORF15+714A>T (stop)
ORF15Lys238Ter
c.2467A>T
p.Lys823fs
Pelletier et al., 2006 [
14]
2249
RPGR (ORF15)
g.ORF15+747_748insTG
ORF15Glu249fs
c.2499_2500dupTG
p.Glu834fs
novel mutation
24745
RPGR (ORF15)
g.ORF15+748delA
ORF15Glu249fs
c.2501delA
p.Glu834fs
Bader et al., 2003 [9]
2604
RPGR (ORF15)
g.ORF15+753delG
ORF15Glu251fs
c.2506delG
p.Glu836fs
Pelletier et al., 2006 [
14]
10005°
RPGR (ORF15)
g.ORF15+795delG
ORF15Glu265fs
c.2548delG
p.Glu850fs
Prokisch et al., 2007 [52]
24731°
RPGR (ORF15)
g.ORF15+795delG
ORF15Glu265fs
c.2548delG
p.Glu850fs
Prokisch et al., 2007 [52]
2678
RPGR (ORF15)
g.ORF15+801_802insG
ORF15Glu267fs
c.2554dupG
p.Glu852fs
Bader et al., 2003 [9]
25333
RPGR (ORF15)
g.ORF15+833_834delGG
ORF15Glu278fs
c.2586_2587delGG
p.Glu863fs
Yokoyama et al., 2001 [53]
2865
RPGR (ORF15)
g.ORF15+875_876delGG
ORF15Glu292fs
c.2628_2629delGG
p.Glu877fs
Push et al., 2002 [54]
2814
RPGR (ORF15)
g.ORF15+1087_1088ins22
ORF15Glu365fs
c.[2820_2840dup21; 2840dupA]
p.Glu950fs
novel mutation
XRP23
RPGR (ORF15)
g.ORF15+1254_1257delGGAG
ORF15Gly418fs
c.3007_3010delGGAG
p.Gly1003fs
Sharon et al., 2003 [15]
24747**
RPGR (ORF15)
g.ORF15+1339delA
ORF15Glu446fs
c.3092delA
p.Glu1031fs
Bader et al., 2003 [9]
2557°°
RPGR (ORF15)
g.ORF15+1642delA
ORF15Asn547fs
c.3395delA
p.Asn1132fs
novel mutation
The 
table
 
shows 
families
 
with 
at 
least 
two 
affected
 
males 
and 
no 
male
 
to 
male
 
transmission. 
A 
degree 
symbol 
(°) 
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cases 
with 
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dominant
 
inheritance
pattern.
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the
additional
 
deletion
 
does 
not 
remove 
parts 
of 
the 
coding 
region 
of 
exon 
ORF15 
and 
deletes
 
6419 
bp 
including
 
exon 
15a 
and 
15b. 
Two 
asterisks 
(**) 
indicate 
that 
the
mutation
 
of 
this 
patient
 
ID 
was 
identified
 
two 
times. 
Four 
asterisks 
(****) 
and 
five 
asterisks 
(*****) 
show 
that 
the 
mutation
 
was 
identified
 
four 
and 
five 
times,
respectively.
 
The 
mutations
 
are 
either
 
presented 
in 
approved 
nomenclature
 
according 
to 
Human Genome Variation Society
 
(2) 
or 
as 
recommended
 
by 
Bader 
et 
al.,
2003 [9] and Sharon et al., 2003 [15] (1) (
BC043348 and NM_001034853 were used as reference sequence for, respectively, 
RP2 and RPGR mutation analysis).
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10851A,  Table  1).  None  of  these  sequence  alterations  were
identified in 100 to 300 control alleles. Sequence alterations
summarized in Table 3 likely represent polymorphisms.
RPGR  ORF15  mutations  were  neither  detected  in  39
simplex male cases with RP, nor in six simplex male cases
affected by cone-rod dominated degenerations.
Analyses of a retinitis pigmentosa family with an assumed
dominant inheritance pattern: Among the six families with
dominant inheritance pattern, we found three deletions in exon
ORF15 of RPGR. In one of these six families (index patient
25085,  Figure  3A)  linkage  analysis  by  microsatellite
genotyping was performed and excluded seven known ADRP
loci. Sequencing of PRPF31, RDS, RHO, HPRP3, and PRPF8
did not reveal causative mutations. Microarray-based linkage
analysis suggested an 11.5 Mb region on the X-chromosome
comprising the RPGR gene.
Subsequent analysis of RPGR identified a 2 bp deletion
within  the  alternatively  spliced  exon  ORF15  (c.
2405_2406delAG, Table 1). This deletion was predicted to
result in a frameshift, an altered amino acid composition, and
a premature stop codon after 97 bp truncating the full length
protein by 320 amino acids. In addition, an in-frame 12 bp
TABLE 2. POLYMORPHIC SEQUENCE VARIATIONS IN EXON ORF15 OF RPGR FOUND IN X-LINKED RETINITIS PIGMENTOSA PATIENTS
Patient Deletions or duplications found in
exon ORF15 (1)
Deletions or
duplications found in
exon ORF15 (2)
Nucleotide
substitutions found in
exon ORF15 (1)
Nucleotide
substitutions
found in exon
ORF15 (2)
Protein change
resulting from
nucleotide
substitutions (1) (2)
24731 g.ORF15+1060_1080dup21 c.2813_2833dup21 g.ORF15+1643C>T c.3396C>T p.N547N / p.N1132N
24731 - - g.ORF15+1677G>A c.3430G>A p.V559I / p.V1144I
24747 - - g.ORF15+1643C>T c.3396C>T p.N547N / p.N1132N
24747 - - g.ORF15+1677G>A c.3430G>A p.V559I / p.V1144I
2678 - - g.ORF15+1813A>C c.3566A>C 3'UTR
2814 - - g.ORF15+1643C>T c.3396C>T p.N547N / p.N1132N
2814 - - g.ORF15+1677G>A c.3430G>A p.V559I / p.V1144I
2814 - - g.ORF15+1813A>C c.3566A>C 3'UTR
2865 g.ORF15+1307_1318delAGTGGAAGGGGA c.3060_3071del12 - - -
3044 g.ORF15+914_916delGGA c.2667_2669del3 g.ORF15+588G>A c.2341G>A p.A196T / p.A781T
25085 g.ORF15+1307_1318delAGTGGAAGGGGA c.3060_3071del12 - - -
The sequence alterations are either presented in approved nomenclature according to Human Genome Variation Society (2) or
as recommended by Bader et al., 2003 [9] and Sharon et al., 2003 [15] (1) (BC043348 and NM_001034853 were used as reference
sequence for, respectively, RP2 and RPGR mutation analysis).
TABLE 3. POLYMORPHIC SEQUENCE VARIATIONS IN EXONS 1 TO 15 OF RPGR FOUND IN X-LINKED RETINITIS PIGMENTOSA PATIENTS
Patient ID
Position in
RPGR
Nucleotide substitutions                                              Heterozygosity                   Protein
found in RPGR exons 1 to 15 SNP ID              frequency                    change
24731 intron 1 c.29-15G>A rs6651585 0.474 +/- 0.110 -
24745 exon 10 c.1164G>A rs1801686 0.189 +/- 0.242 p.A388A
24747 intron 1 c.29-15G>A rs6651585 0.474 +/- 0.110 -
24747 exon 9 c.1033A>G - 0.007** p.N345D
2249 exon 11 c.1367A>G - - p.Q456R
2604 exon 10 c.1164G>A rs1801686 0.189 +/- 0.242 p.A388A
2814 exon 9 c.1033A>G - 0.007** p.N345D
2814 intron 12 c.1507-101A>T rs5918520 - -
2557 intron 12 c.1507-101A>T rs5918520 - -
24520 intron 12 c.1507-101A>T rs5918520 - -
25428 intron 1 c.29-15G>A rs6651585 0.474 +/- 0.110 -
25428 exon 9 c.1033A>G - 0.007** p.N345D
25428 intron 12 c.1507-101A>T rs5918520 - -
24748* intron 4 c.310+10T>C - - -
The  sequence  alterations  are  presented  in  approved  nomenclature  according  to  Human  Genome  Variation  Society
(NM_001034853 was used as reference sequence for mutation analysis). The asterisk (*) indicates that this sequence variant
was not detected in over 300 control alleles. The two asterisks (**) indicate that this value was published by Sharon et al., 2000
[15].
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IDdeletion, previously described as a polymorphism [9], was
found in each patient with the 2 bp deletion. This suggested
that both deletions were located on the same allele. The 12 bp
deletion was further downstream of the 2 bp deletion and
affected positions c.3060_3071del12. No additional sequence
alteration was identified in RP2 and RPGR. The segregation
of the deletions was in accordance with linkage data.
The  mutation  was  identified  in  four  males  and  four
females of the family, whereas six healthy female relatives did
not carry the mutation (Figure 3A). All male mutation carriers
showed  the  RP  phenotype,  whereas  only  two  of  the  four
female carriers were affected (Figure 3A). In this family, the
ORF15  mutation  caused  a  variable  heterozygote
manifestation  of  the  phenotype  in  females,  although  the
majority  of  previously  reported  RPGR  mutations  are
recessive.
Clinical  evaluation  and  interviews  with  the  patients
showed that the course of the disease, with respect to age-of-
onset and disease progression, varied both in affected males
and females. Males reported awareness of visual impairment
between seven and 24 years of age, and disease progression
varied  from  slow  to  rapid.  Females  first  noticed  visual
impairment at 24 years (II:2), 28 years (III:7), and 32 years
(II:3). Individual II:3 (mother of III:12; 61 years old) rapidly
Figure  2.  Characterization  of  the
deletion breakpoint in patient 2557. A:
Schematic  drawing  of  RPGR  exons
ORF15, 15a, and 15b. Primers used for
long-range PCR are marked by arrows
and flank the 6419 bp deletion. B: Long-
range PCR for patient 2557 (male) and
a control sample (male). The difference
of the PCR products represents the 6.4
kb  deletion  in  patient  2557.  C:  The
sequence profile shows the breakpoint
of the deletion in patient 2557. The open
reading frame of exon ORF15 was not
affected by the deletion. In total, 6419
bp were deleted, starting 27 bp after the
stop codon in ORF15 and ending 72 bp
after exon 15a. Note that exon 15a is
downstream of 15b. Thus, the deletion
affected  both  exons  15a  and  15b  of
RPGR.
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1087Figure 3. Characterization of a family with X-linked retinitis pigmentosa and variable expressivity in mutation carriers. A: Pedigree with three
generations. Circles represent females and squares represent males. Slashed symbols indicate deceased family members. Filled black symbols
denote family members with retinitis pigmentosa (RP), and circles with a dot indicate female mutation carriers who had no history of visual
complaints. Horizontal bars designate family members whose genotype was determined by molecular genetic testing. Arrow marks the index
patient 25085. The mutation c.2405_2406delAG in exon ORF15 of RPGR segregates with the disease in males, and shows variable
heterozygote manifestation in females. B: Fundus pictures of three affected family members show typical pigmentations found in the peripheral
retina of patients with RP. Patient age and gender are provided below each fundus photograph. C: Pattern of X-chromosome inactivation of
selected female family members. None showed a unilateral X-inactivation at the AR-locus. The following abbreviations and symbols are used:
control nonrandom X-inactivation (C-nr), control random X-inactivation (C-r), HpaII digestion (+), and no HpaII digestion (-).
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1088lost vision within a few years, a disease course similar to the
male family member III:4, who reported normal vision until
age 24, followed by rapid visual loss. In contrast to the severe
course of the disease in female II:3, kinetic perimetry, scotopic
and  photopic  ERG,  and  dark  adaptation  indicated  mild
expression of RP in III:7 eight years after the diagnosis was
made.  However,  she  had  pigmentary  deposits  in  the
midperiphery of her fundus (Figure 3B).
The phenotypic variability within female carriers of the
family  might  be  caused  by  an  altered  X-chromosomal
inactivation.  We  analyzed  the  X-inactivation  pattern  in
different family members, but did not find skewed signal
intensities in any of the symptomatic female carriers (Figure
3C).
DISCUSSION
We identified 17 novel and 16 known mutations in RPGR and
RP2 by screening of 141 DNA samples from RP patients. In
the subgroup of 90 possible XLRP families, including also
male sibships, we identified five different RP2 mutations and
28  distinct  pathogenic  sequence  alterations  in  RPGR.
Approximately 35% of the XLRP families described herein
showed mutations in exon ORF15 of RPGR. This detection
rate for ORF15 mutations was within the range found in other
studies  [8,14].  RPGR  exon  ORF15  mutations  have  been
reported to occur either in 30% or 52% in North American
families with XLRP [15,40], whereas 43% were reported for
Spanish cohorts [41]. Furthermore, detection rates of 49%
have been described for families from France and 60% for
families from the UK/Ireland [11,14].
Of  all  published  RPGR  mutations,  55%  have  been
reported to reside in exon ORF15 [1]. We detected a total of 37
RPGR mutations, including 31 located to exon ORF15. Thus,
we identified over 80% of the RPGR mutations in ORF15, a
proportion  higher  than  described  recently  [1].  These
variations in detection rates might be due to different ethnical
backgrounds of the patient cohorts.
Up to 28% of sporadic XLRP cases from France were
reported to carry mutations in exon ORF15 of RPGR [14]. In
contrast, we did not find ORF15 mutations in 39 sporadic
cases from Switzerland. This difference again indicates that
the  ethnical  background  of  the  cohorts  influences  the
detection rate. Nevertheless, it might also be necessary to pre-
select sporadic cases for early-onset RP phenotypes, as done
by Pelletier et al. [14], to increase the chance to identify
ORF15 mutations in sporadic cases.
In  one  XLRP  family,  we  found  the  mutation  c.
968delAinsTCC in RP2. This pathogenic sequence alteration
deletes a single nucleotide and inserts three novel nucleotides
at the same position. It leads to a frameshift starting in exon
4 and was predicted to result in a premature stop in exon 5.
Moreover,  the  mutation  inserts  three  nucleotides  in  the
penultimate position in exon 4 of RP2 and thus alters the
consensus sequence of the splice donor site. This might lead
to mis-splicing with increased exon 4 skipping from RP2
transcripts. The position of this mutation is, to the best of our
knowledge, the most 3’-terminal disease-associated variant in
RP2 identified so far. This also holds true for the mutation c.
3395delA (patient 2557) in exon ORF15 of RPGR. In the same
patient,  an  additional  deletion  of  approximately  6.4  kb
removing  RPGR  exons  15a  and  15b  was  identified,  a
rearrangement that helped to identify the gene in 1996 [39].
In this study, we determined the breakpoint of this 6.4 kb
microdeletion and found that the coding region of ORF15 was
not  affected.  In  contrast,  the  mutation  c.3395delA
(p.Asn1132fs) of patient 2557 leads to a frameshift in the 3’-
terminal part of ORF15 and alters the composition of the last
21 amino acids of RPGR, which are not part of the repetitive
and  highly  charged  region  in  ORF15.  Interestingly,  3’-
terminal mutations in RPGR exon ORF15 are occasionally
associated with cone-rod degenerations rather than classic RP
[19-21,42]. However, in the case described herein, a typical
RP phenotype was observed. It is not clear whether or not the
microdeletion of over 6.4 kb influenced the phenotype in
patient 2557.
Disease expression in males with RPGR mutations is
severe. It has been shown previously that the phenotype of
female  carriers  of  pathogenic  RPGR  mutations  is  highly
variable. Some exhibit severe symptoms, while others are
asymptomatic. We have identified three pathogenic sequence
alterations in the mutational hot spot exon ORF15 that lead to
disease expression also in female carriers. The mutation c.
2548delG was found in a family in which the mother, in
addition to three of her sons, was affected. The same mutation
occurred in a second family with reduced disease expression
in female carriers (family 10005). The finding that a mutation
leads to a phenotype only in a fraction of female carriers could
be due to genetic modifiers. We identified additional in-frame
variations in ORF15 that might influence the clinical picture
in  female  carriers.  Nevertheless,  in-frame  deletions  and
duplications were frequently described as polymorphisms of
exon ORF15, which makes it unlikely to be the only factor
causing the differences found in carriers. Other modifiers such
as  age,  environmental  factors,  additional  changes  in  the
second allele of the carrier females, or genetic variability in
other genes may influence the disease expression. Further
investigations  will  identify  and  characterize  the  possible
modifiers  that  determine  the  clinical  outcome  of  RPGR
mutations in female carriers. In contrast, no RP2 mutations
have  been  described  that  result  into  heterozygote  carrier
manifestations.
The mutation c.2405_2406delAG, found in one of the
families with assumed dominant inheritance of this study, has
been described previously [43,44]. The family characterized
here showed severe retinal degeneration in males and mild
(III:7) to severe (II:3) ocular symptoms in two female carriers.
Moreover, we identified two female mutation carriers who
Molecular Vision 2008; 14:1081-1093 <http://www.molvis.org/molvis/v14/a129> © 2008 Molecular Vision
1089had no history of visual complaints: II:7 (51 years old) and
III:11 (29 years old). In accordance with Rozet et al. [43], we
conclude that this mutation leads to variable heterozygote
manifestation of the phenotype. With the assumption that the
families are unrelated, this observation suggests a genotype-
phenotype correlation associated with the RPGR mutation c.
2405_2406delAG. We also identified an additional in-frame
(12 bp) deletion in all carriers of the pathogenic 2 bp deletion.
It is likely that the 12 bp deletion represents a polymorphism
as described by Bader et al. [9], although an additional effect
on the phenotype cannot be excluded. Skewed X chromosome
inactivation as an explanation of the largely variable disease
manifestations in females was not supported by our data. Full
expression of disease symptoms in females with an RPGR
mutation  may  be  misleading  in  molecular  analyses  and
genetics counseling. Thus, ORF15 mutations in RPGR should
be excluded in families that seem to fit an AD pattern of RP,
but lack male-to-male transmission.
We propose a screening strategy for routine molecular
genetics testing of possible XLRP cases by direct sequencing.
Between 30% and 80% of mutations are found in exon ORF15
of RPGR [40,45], followed by mutation frequencies that are
similar  for  RP2  and  RPGR  exons  1  through  15.  In  total,
approximately 70%–80% of XLRP cases carry mutations in
RPGR and up to 20% in RP2. Based on these results and to
keep costs low, we recommend beginning with the screening
of an XLRP male patient by ORF15 mutation analysis. Our
approach to amplify the complete exon ORF15 in a single
PCR reaction reduces costs and effort. After identification of
an  ORF15  mutation,  the  molecular  diagnosis  might  be
considered as confirmed, since patients with an additional
mutation in exons 1 through 15 of RPGR and RP2 have not
been reported. Nevertheless, this cannot be excluded, and a
complete screening of known XLRP genes should be offered.
In addition, the segregation of the ORF15 mutation within the
family might be verified. If no ORF15 mutation is identified,
we recommend to continue the screen for mutations with RP2
rather than RPGR. This recommendation is based on the fact
that RP2 is composed of five exons only, whereas 15 exons
need to be screened to complete the sequence analysis of
RPGR without any clear benefit in terms of likelihood to
detect the causative mutation.
So far, no RP2 mutation has been identified in families
with likely dominant inheritance pattern, except for a single
case,  where  the  only  affected  female  showed  a  structural
chromosome aberration and a unilateral X-inactivation due to
a  balanced  X-autosome  translocation  [14].  In  contrast,
dominant inheritance was reported for a couple of RPGR
mutations [43,46]. Furthermore, ORF15 mutations have also
been associated with phenotypes of the central part of the
retina, including cone-rod or cone dystrophies and atrophic
macular  degeneration  [19-21,42].  Consequently,  in  XLRP
cases with manifestations of the phenotype in females or in
patients  with  X-linked  cone-dominated  retinopathies,  we
recommend  screening  exon  ORF15  first,  followed  by  the
other exons of RPGR.
In addition to the phenotype of RP, mutations in exons 6,
8, and 10 of RPGR have been associated with features of
primary ciliary dyskinesia, hearing dysfunction, sinusitis, and
recurrent  infections  [47-50].  Thus,  in  XLRP  cases  with
additional phenotypes, the best candidate region of RPGR
seems to be exons 1 through 15.
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